Background {#sec1_1}
==========

Aging is related to a decrease in muscle mass and an increase in fat mass, which corresponds with an increased risk for metabolic disorders, type 2 diabetes, and cardiovascular complications \[[@B1],[@B2],[@B3],[@B4]\]. The relative loss of fat-free mass (FFM), an increase in fat mass, and abdominal fat distribution are further associated with physical impairments and a higher mortality rate \[[@B5],[@B6],[@B7]\]. Increased abdominal adipose tissue causes unfavorable changes in insulin sensitivity and plasma lipid values \[[@B8],[@B9]\]. Subclinical inflammation of adipose tissue surrounding and infiltrating muscles is supposed to be one mechanism responsible for the muscular abnormalities in the aging process \[[@B10]\]. In obese patients, exaggerated loss of muscle mass can result in sarcopenic obesity \[[@B11],\] with a further increase in the cardiovascular risk \[[@B12]\].

One of the most important and effective developments in the pharmacological interventions to reduce cardiovascular complications was the introduction of statin therapy. Landmark studies and meta-analyses clearly demonstrated that statin therapy results in a significant reduction of cardiovascular morbidity and mortality \[[@B13],[@B14]\]. This is also supported by recently published data from the Cholesterol Treatment Trialists' meta-analysis including data from \>170,000 participants from 26 randomized statin trials \[[@B15]\]. In general, statins are well tolerated and safe, with myopathy as the most serious negative side effect \[[@B15],[@B16],[@B17]\]. Muscular damage during statin therapy ranges from muscle weakness, aches, and fatigue to rhabdomyolysis with the potential risk of renal failure. The occurrence of general myopathies has been estimated to range from 1 to 10%, while rhabdomyolysis was reported to occur in 0.1% of all statin users \[[@B14],[@B17]\]. The creatine phosphokinase (CPK) plasma levels serve as an indicator for muscle cell damage and death \[[@B14]\], but are also related to muscle mass \[[@B18],[@B19]\]. The risk of myopathy under statin therapy increases with an increasing dosage of the statin, in the case of multiple medication, and especially in elderly individuals \[[@B17]\].

Recently published retrospective analyses of statin studies indicate that statin therapy -- despite the tremendous preventive effects on cardiovascular disease -- might cause an increased risk of type 2 diabetes \[[@B20],[@B21],[@B22]\]. Evidence for a dose-dependent association between statin and diabetes risk was described in a meta-analysis \[[@B22]\], but the underlying mechanisms remain a matter of speculation. It could be hypothesized that distinct effects of statin therapy on muscle cells result in muscle insulin resistance \[[@B23]\]. Statin therapy could also affect the age-associated decrease in muscle strength and muscle mass \[[@B1],[@B24],[@B25]\]. Myopathy under statin therapy is multifactorial. A modulation of the respiratory chain of mitochondria \[[@B26],[@B27]\], an increase in muscle cell apoptosis \[[@B16]\], and an upregulation in the expression of genes that modulate membrane repair were described as a part of the complex underlying mechanism of statin myopathy \[[@B28]\].

Regarding the debate about a possibly increased incidence of type 2 diabetes under statin therapy and the side effects of statins on muscle cells, it seemed of interest to us to study whether statin therapy is related to an exaggerated aging-associated decrease in FFM. For this purpose, a cohort of patients with and without statin therapy was assigned to different age groups. To analyze the effect of statin use on the FFM, we regress a patient\'s FFM on the statin use and on other control variables.

Patients and Methods {#sec1_2}
====================

Between January 2005 and July 2011, a total of 3,280 persons attended a medical outdoor center for diagnostic and/or therapeutic interventions. All patients underwent clinical routine controls and laboratory measurements. The level of physical exercise was determined by the reported frequency of sporting activities per week.

Laboratory tests were performed from blood samples taken in the morning after an overnight fasting period. Patients were asked to restrain from vigorous physical exercise 48 h before the laboratory and clinical measurements were performed. Total CPK activity was determined by 'Menarini autoanalyzer reagent FGENT CK-NAC MONO', and normal CPK activity ranged from 24 to 170 U/l.

Body composition (lean mass, fat mass, proportion of fat mass) of the patients was estimated using bioelectrical impedance analysis with body composition monitor HBF-306-E 'OMRON' bipolar devices \[[@B29],[@B30]\]. Information on BMI and on FFM was collected from all patients \[[@B29],[@B30]\].

Patients were assigned to 3 age groups from ℋ60 to \>75 years of age, thereby also separating patients with and without statin therapy. The patients were defined as statin users when a continuous intake of statins was reported for at least 4 weeks (duration of medication 1--78 months). A sub-analysis was performed for patients under statin therapy with CPK values in the normal range compared to those with CPK values above 170 U/L. None of the patients revealed renal impairments. A further assignment of the patients into 3 groups was performed according to the body mass index (BMI) -- with normal BMI (ℋ25 kg/m^2^), overweight (25--30 kg/m^2^), and obesity (\>30 kg/m^2^).

Patients with acute vascular complications (myocardial infarction, coronary interventions, stroke, cerebral ischemia within 12 weeks), acute or chronic inflammatory disease, severe renal or hepatic failure or chemotherapy, or non-statin lipid-lowering drug therapy were excluded from our evaluation.

No changes in lifestyle during the last 3 months were stated by the patients, and none of the patients reported about a current weight reduction program. Beside the clinical status, an increased erythrocyte sedimentation rate, C-reactive protein and leukocyte count were the diagnostic criteria for inflammatory disease. Renal disease was defined by a serum creatinine \>1.5 mg/dl and impaired liver function by a double or higher increase of hepatic enzyme levels.

The share of people engaging in regular sports activities was about 43%, while approximately 24% patients in our sample were smokers and 11% were patients with diagnosed type 2 diabetes mellitus.

Informed consent about the participation in the study was requested from all of the patients.

Statistical Analysis {#sec2_1}
--------------------

First of all, we applied a descriptive analysis by which we compared FFM of statin users and non-statin users across different age cohorts. Furthermore, in order to analyze the impact of statin use on FFM more systematically, we regressed a patient\'s FFM on an indicator variable informing about statin use, an interaction term between statin use and age, and other control variables. The latter include a patient\'s age (in years), gender (dummy variable, entry 1 indicating male patients), and two indicator variables informing about nicotine consumption (entry 0 for non-smokers and entry 1 for smokers) and sporting activities (entry 1 for patients engaging in sporting activities at least once a week, and entry 0 for all other patients). In all regressions, we used standard ordinary least-squares methods and excluded outlying observations at the upper and lower percentile of the remainder error (2% of the sample, or about 60 observations). We applied our regressions to two samples, one including all patients and one including only patients with CPK levels below 170 U/l.

Results {#sec1_3}
=======

In the whole study cohort of 3,280 patients a total of 600 patients were on continuous statin therapy, and 2,680 were non-users of statins. The highest frequency of statin prescription was in the age group 60--75 years. 131 (21.8%) of the patients on continuous statin therapy revealed increased CPK values. None of them developed an impaired renal function.

BMI revealed a decrease, with the lowest values in the oldest age group, i.e. \>75 years, in patients with and without statin therapy (table [1](#T1){ref-type="table"}). FFM decreased continuously with increasing age. The loss of FFM between the age group ℋ60 years and \>75 years was more pronounced in statin-treated patients (10.88%) than in non-statin users (8.47%). This was paralleled by a decrease in CKP-values, with a difference of 7.77 U/l between the age groups ℋ60 and \>75 years in non-statin users and of 14.75 U/l in statin users.

In statin users and in non-statin users the percentage of fat mass increased continuously with aging, with the highest values in the age group \>75 years. In all age groups the BMI and corresponding FFM values were higher in statin users than in non-statin users (table [1](#T1){ref-type="table"}), whereas a higher percentage of fat mass was only observed in the younger study group ℋ60 years of age. Fasting glucose levels revealed a continuous increase with increasing age in non-statin users and in statin users.

With respect to the data evaluation according to subgroups defined by the BMI values, non-statin users in the overweight and obese groups (25--30 kg/m^2^ and \>30 kg/m^2^) were older than in the normal-weight group (ℋ25 kg/m^2^) (table [1](#T1){ref-type="table"}). Overall, statin users were older than non-statin users. The percentage of body fat mass in the BMI group ℋ25 kg/m^2^ was higher in statin users than in non-statin users, while no such pronounced difference was found for overweight or obese patients. In all BMI groups statin users -- except those with increased CPK values -- showed lower values for FFM than non-statin users. Fasting glucose and triglyceride values revealed a continuous increase with increasing BMI in statin users and in non-statin users. In the BMI subgroups fasting glucose and triglyceride levels were higher in statin users compared to non-statin users (table [1](#T1){ref-type="table"}).

A more systematic picture of the relationship between FFM and statin use is provided in our regression results in table [2](#T2){ref-type="table"}. First of all, it can be seen that male patients obtained a higher FFM than female patients. Furthermore, age was associated with a lower FFM. Nicotine consumption and sporting activities played an insignificant role. Additionally, we found a (highly) significant parameter estimate for statin use, indicating that patients undergoing a corresponding therapy revealed a higher FFM. We also observed that this effect of statin therapy declined over age, which is indicated by the significantly negative coefficient on the interaction term between statin use and the age variable. This, in turn, suggests that the effect of statin therapy on FFM is more pronounced in younger patients than in older ones. Both findings, i.e. the positive coefficient on the statin variable and the negative one on the interaction term between statin use and age, are in accordance with the descriptive evidence from table [1](#T1){ref-type="table"}. In conclusion, we cannot see any systematic differences regarding the effects of statin therapy on FFM (and also its change over years) between our sample of all patients and the one focusing on 2,613 patients, with CPK equal to or lower than 170 U/l (columns 1 and 2 in table [2](#T2){ref-type="table"}).

Discussion {#sec1_4}
==========

The results of our evaluation indicate that patients under statin therapy reveal a more pronounced aging-associated decrease in FFM between the age groups of ℋ60 and \>75 years than in patients without statin therapy. This loss of FFM could be due to the complex morbidity of statin-treated patients but also due to a possible direct influence on FFM. Multivariate analysis revealed a strong positive relationship of FFM to male sex and to statin use. The association of FFM with male sex is well known and explained by the anabolic hormone effects \[[@B31],[@B32]\].

BMI and FFM values were higher in all of the patients treated with statin than in those without statin therapy. This observation could partially be due to a higher level of physical exercise \[[@B33]\]. Recently published studies reported an increased lean mass following resistance training under statin therapy and a more favorable outcome during rehabilitation procedures in elderly patients \[[@B34],[@B35]\]. As body weight and BMI are indicators of FFM \[[@B36],\] the higher FFM in our statin patients might simply be explained by the higher BMI values.

CPK activity is known to be related to FFM \[[@B18],[@B19]\]. Low CPK levels are related to muscle weakness \[[@B37]\], sarcopenia, and frailty \[[@B38]\]. In all of our patients, the lowest values for CPK, BMI and FFM were found in the oldest age group, in statin-treated patients, and in those without statin therapy. This finding is in accordance with previously published epidemiological data and clinical studies concerning a decrease of BMI at an advanced age \[[@B39],[@B40]\], resulting in an increased risk for physical impairment and frailty \[[@B2]\].

Fat mass increases with increasing age \[[@B5],[@B6]\] and is related to a higher cardiometabolic risk, but also to a higher rate of muscle loss and sarcopenia \[[@B12]\]. Greater total and abdominal adipose tissue mass is associated with subclinical inflammation \[[@B41]\], a process possibly enhancing sarcopenia \[[@B42]\]. Because statins also show anti-inflammatory effects, it could be speculated that statins improve sarcopenia \[[@B43]\]. Recently, an improved outcome during inpatient rehabilitation was described during statin therapy in older people; however, no measurements on FFM were provided \[[@B35]\].

Fasting glucose values of all our patients revealed an increase with increasing age, and peak fasting glucose levels were found in patients \>75 years with and without statin therapy. This aging-associated increase in fasting glucose levels was also described by several other studies \[[@B44],[@B45]\] and is primarily explained by the aging-associated increase in insulin resistance. In accordance with this, we could observe an increase in fat mass with increasing age, with a higher risk for insulin resistance \[[@B8],[@B9]\].

In patients without statin therapy, total cholesterol increased up to the age group of 60--74 years and decreased thereafter. This could be explained by aging-associated impairments of lipoprotein metabolism resulting in an increase in total cholesterol \[[@B46],[@B47]\]. Total cholesterol was the lowest in the age group \>75 years, which was paralleled by a decrease of serum triglycerides in patients with statin therapy. This might be related to reduced food intake, with a high risk for malnutrition at an advanced age \[[@B2]\].

Limitations of our evaluation are the fact that all study participants were patients admitted to an outdoor center and not a cohort of healthy individuals. However, all of our study participants were community-dwelling subjects without significant functional impairments.

Our findings indicate that patients under statin therapy reveal a more pronounced decrease in FFM than patients without statin therapy. It remains speculative whether this relationship is causal as a consequence of statin myopathy or due to the higher morbidity in patients needing statin therapy. Considering statin long-term safety \[[@B48],\] further studies will be required especially for patients at an advanced age.

Conclusions {#sec1_5}
===========

Patients under statin therapy revealed a more pronounced aging-associated decline in FFM than patients without statin therapy. Aging was related to an increase in fat mass in statin users and non-users, which was paralleled by an increase in fasting glucose values. Interventions to prevent a more pronounced decline in muscle mass could be of particular advantage for elderly patients under statin therapy.
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###### 

Sample characteristics

  Age cohort                          Observed   BMI     BFM     FFM     CPK      FGL      Total c   TG
  ----------------------------------- ---------- ------- ------- ------- -------- -------- --------- --------
  ***Non-statin users***                                                                             
  \<60                                1,978      24.08   23.80   52.99   119.34   93.71    203.94    114.46
  60--75                              404        26.10   32.40   50.87   122.73   108.38   227.73    131.29
  \>75                                298        24.58   34.54   44.52   111.57   113.00   219.82    130.34
  Total                               2,680      24.44   26.29   51.73   118.99   98.10    209.34    118.80
  ***Statin users***                                                                                 
  \<60                                152        27.46   29.28   58.37   133.18   113.20   226.46    176.99
  60--75                              293        26.68   32.53   51.85   135.78   113.93   210.17    151.18
  \>75                                155        25.84   34.68   47.49   118.43   116.48   212.76    138.69
  Total                               600        26.66   32.26   52.38   130.64   114.40   214.98    154.50
  ***Statin users with CPK\> 170***                                                                  
  \<60                                39         28.35   29.10   60.99   232.24   117.96   227.02    177.98
  60--75                              69         27.07   32.14   53.60   260.70   111.93   199.20    164.93
  \>75                                23         26.16   33.38   50.36   268.70   128.20   207.43    145.04
  Total                               131        27.29   31.45   55.23   253.63   116.59   208.93    165.32

  BMI cohort                           Observed   Age     BFM     FFM     CPK      FGL      Total c   TG
  ------------------------------------ ---------- ------- ------- ------- -------- -------- --------- --------
  ***Non-statin users***                                                                              
  \<25                                 1,656      43.70   22.83   48.02   109.81   93.94    205.35    103.96
  25--30                               706        52.86   29.69   56.19   136.61   102.21   216.53    138.88
  \>30                                 317        52.60   36.80   61.10   127.78   110.43   214.01    150.86
  Total                                2,679      47.17   26.29   51.72   119.00   98.10    209.34    118.80
  ***Statin users***                                                                                  
  \<25                                 225        68.67   29.07   46.45   125.25   107.63   218.96    140.62
  25--30                               253        66.76   32.33   54.37   130.59   112.53   213.37    153.93
  \>30                                 122        65.53   37.99   59.18   140.70   130.60   211.06    181.06
  Total                                600        67.23   32.26   52.38   130.64   114.40   214.98    154.50
  ***Statin users with CPK \> 170***                                                                  
  \<25                                 44         67.84   28.41   48.82   260.22   107.34   217.79    171.87
  25--30                               55         65.02   31.02   55.97   254.90   114.50   207.03    156.15
  \>30                                 32         64.07   36.38   62.77   242.39   132.88   200.00    172.07
  Total                                131        65.73   31.45   55.23   253.63   116.59   208.93    165.32

BFM = body fat mass in %; FFM = fat-free mass in %; CPK = creatine phosphokinase (U/l); FGL = fasting glucose (mg/dl); total c = total cholesterol (mg/dl); TG = triglycerides (mg/dl).

###### 

Impact of statin therapy on fat-free mass[^a^](#T2F1){ref-type="table-fn"}

                                           All patients                                           Patients with CPK ≤ 170
  ---------------------------------------- ------------------------------------------------------ ------------------------------------------------------
  Sex (1 = male)                           16.9298 (0.2465)[\*\*\*](#T2F2){ref-type="table-fn"}   16.4383 (0.2799)[\*\*\*](#T2F2){ref-type="table-fn"}
  Age                                      −0.1274 (0.0069)[\*\*\*](#T2F2){ref-type="table-fn"}   −0.1281 (0.0075)[\*\*\*](#T2F2){ref-type="table-fn"}
  Nicotine consumption (0 = no; 1 = yes)   0.1427 (0.2742)                                        0.0274 (0.2915)
  Sports activity (0 = no; 1 = yes)        0.1164 (0.2285)                                        0.3669 (0.2495)
  Statin use                               7.4048 (1.8506)[\*\*\*](#T2F2){ref-type="table-fn"}    7.0191 (2.0611)[\*\*\*](#T2F2){ref-type="table-fn"}
  Statin use × age                         −0.0947 (0.0274)[\*\*\*](#T2F2){ref-type="table-fn"}   −0.0859 (0.0305)[\*\*\*](#T2F2){ref-type="table-fn"}
  Observations                             3.214                                                  2.613
  *R* ^2^                                  0.64                                                   0.62

Constant suppressed. Standard errors in parentheses.

Indicates significance at the 1% level.
